Ticker Details
Agenus Inc. Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
IPO Date:	February 4, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$129.51M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.12 | 3.49%
Avg Daily Range (30 D):	$0.17 | 4.26%
Avg Daily Range (90 D):	$0.15 | 4.16%

Institutional Daily Volume
Avg Daily Volume:	1.34M
Avg Daily Volume (30 D):	.95M
Avg Daily Volume (90 D):	.74M

Trade Size
Avg Trade Size (Sh.):	264
Avg Trade Size (Sh.) (30 D):	129
Avg Trade Size (Sh.) (90 D):	131

Institutional Trades
Total Institutional Trades:	1,263
Avg Institutional Trade:	$1.65M
Avg Institutional Trade (30 D):	$1.34M
Avg Institutional Trade (90 D):	$.95M
Avg Institutional Trade Volume:	.04M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.76M
Avg Closing Trade (30 D):	$1.34M
Avg Closing Trade (90 D):	$.95M
Avg Closing Volume:	39.36K

News

Feb 18, 2026 @ 4:00 PM CTLA-4 Inhibitors Competitive Landscape Research R... Source: Researchandmarkets.Com

Jan 5, 2026 @ 11:04 PM Agenus (AGEN) Q3 2024 Earnings Call Transcript Source: Motley Fool Transcribing

Aug 28, 2025 @ 2:44 PM FDA Tightens Survival Standards as Cancer Drug Pip... Source: Prnewswire

Aug 18, 2025 @ 5:00 PM PD-(L)1 Inhibitors Market Set to Surge During the ... Source: Delveinsight

Aug 13, 2025 @ 2:00 PM U.S. Pharmaceutical CDMO Market Valuation to Surpa... Source: Towards Healthcare

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$1.66	$1.03	$-.37
Diluted EPS	$1.59	$1.02	$-.37
Revenue	$123.87M	$33.74M	$34.2M
Gross Profit			$34.2M
Net Income / Loss	$62.49M	$39.21M	$-10.61M
Operating Income / Loss	$8.2M	$15.05M	$14.4M
Cost of Revenue	$.89M	$M	$M
Net Cash Flow	$14.57M	$32.01M	$-.46M
PE Ratio

Splits
Apr 12, 2024	1:20
Oct 03, 2011	1:6